---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-011882"
form_type: "8-K"
ticker: "LUCD"
cik: "0001799011"
company_name: "Lucid Diagnostics Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:58:25.963621+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lucid Diagnostics Q2 2025 revenue $1.2M; net loss $7.9M; cash $31.1M after offering

## Summary
- Processed 2,756 EsoGuard tests in Q2 2025; revenue $1.2 million.
- GAAP net loss $7.9M ($0.08 EPS); non-GAAP adjusted loss $9.9M ($0.10 EPS).
- Ended Q2 with $31.1M cash after $16.1M public offering; runway extended into 2026.
- Medicare contractor advisory committee meeting scheduled September 4 for EsoGuard coverage.
- Partnered with Hoag for esophageal precancer testing; joined Russell 2000/3000 indexes.

## SEC filing metadata
- accession: 0001493152-25-011882
- form_type: 8-K
- ticker: LUCD
- cik: 0001799011
- company_name: Lucid Diagnostics Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799011/000149315225011882/0001493152-25-011882-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799011/000149315225011882/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-011882
- JSON: https://secwatch.observer/filing/0001493152-25-011882.json
- Plain text: https://secwatch.observer/filing/0001493152-25-011882.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.